Initial agonist treatment of Parkinson disease: a critique.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 12580185.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The evidence supporting initial dopamine agonist treatment of PD is reviewed. The two rationales for initial agonist treatment are reduced frequency of motor complications and possible relative neuroprotection by dopamine agonists. The basic science supporting these rationales is equivocal. The clinical evidence for advantages of initial agonist treatment is incomplete. More data are required to determine the optimal initial treatment for PD.
Medical subject headings
- Antiparkinson Agents
- Dopamine Agonists
- Membrane Glycoproteins
- Nerve Tissue Proteins
- Neuroprotective Agents
- Parkinson Disease